The scientific leadership rests with Vicent Arbona Mengual of the Department of Biology, Biochemistry and Natural Sciences at Universitat Jaume I. His team also includes Miguel González Guzmán, coordinator of the GaMBiT research group – Genetic and Metabolic Integration of Biotic and Abiotic Interactions – together with Rosario Vidal and Beatriz Julián from the Institute of Advanced Materials (INAM-UJI). The wider consortium spans 11 partners from five countries: Spain, Italy, France, Germany and Sweden. Spanish participants include the Valencian Institute for Agricultural Research and the Galician University–Business Foundation. Italy contributes the Council for Agricultural Research and Economics (CREA) and UNITEC S.p.A., while France is represented by the French Agricultural Research Centre for International Development (CIRAD), the French National Research Institute for Agriculture, Food and Environment (INRAE) and Doriane SAS. Germany’s Computomics GmbH and CYBRES GmbH join the Swedish University of Agricultural Sciences to complete the partnership.

The project’s primary biological targets are sweet orange (Citrus sinensis) and mandarin (Citrus reticulata), two species that dominate global citrus production and consumption. The central objective is to generate genetically modified lines with greater resilience to the adverse conditions caused by climate change and its exacerbating effects on pests and diseases. Rising temperatures, altered rainfall patterns and shifting pest distributions are already straining citrus orchards across the Mediterranean and beyond, making the development of hardier varieties an increasingly urgent agricultural priority. By combining stress physiology expertise with advanced genetic engineering, the consortium aims to produce trees that can maintain productivity under conditions that would compromise conventional varieties.

Resilience is only half of the project’s ambition. CitrusAld also pursues the biofortification of citrus fruits to enhance their nutritional properties. Citrus fruits are widely regarded as functional foods that combine nutritional value with health-promoting properties, thanks to their antioxidant, anti-inflammatory and cardioprotective effects. The project seeks to increase naturally occurring beneficial compounds such as flavonoids and furanocoumarins, while also introducing a compound that citrus does not normally produce: resveratrol. This stilbene, best known as a constituent of grapes and cocoa, has been selected for its cardioprotective and anti-ageing properties. If successful, the work could transform an everyday fruit into an even richer source of bioactive molecules, blurring the line between conventional nutrition and functional food design.

Identifying which genes to modify in a genome as complex as citrus is a formidable challenge, and this is where artificial intelligence enters the project. The consortium will design and implement AI-based systems capable of analysing and integrating large volumes of biological data to pinpoint the most suitable target genes for each desired modification. Rather than relying on laborious trial-and-error approaches, the researchers intend to use computational pipelines that can sift through genomic, transcriptomic and metabolic datasets to prioritise candidate genes whose manipulation is most likely to yield stress tolerance or enhanced nutritional profiles. This data-driven gene discovery methodology represents one of the project’s key methodological innovations and reflects a broader trend of machine learning reshaping plant biotechnology.

Once target genes are identified, the actual genetic modifications will be carried out using New Genomic Techniques, or NGTs, which are now permitted in Europe under the newly updated regulatory framework. These techniques allow precise edits to a plant’s genome without introducing foreign DNA in the way older transgenic methods did, and their recent regulatory acceptance in the European Union has opened the door to projects of this kind. The consortium will also integrate novel materials capable of overcoming existing biological barriers that have historically limited the genetic efficiency of citrus species. Citrus is notoriously difficult to transform genetically, with recalcitrant tissues, long generation times and barriers to regeneration, so the development of new delivery materials could prove as consequential as the gene edits themselves.

In parallel with genome editing, the consortium will explore complementary strategies based on RNA interference technology. RNAi allows researchers to slow down or silence the expression of specific genes without permanently altering the genome, offering a reversible and highly targeted means of modulating plant traits. A central technical hurdle for RNAi in plants is delivering the interfering molecules into plant tissues, where cell walls and other barriers block conventional approaches. The CitrusAld team plans to use novel materials as delivery vehicles into plant tissues, an approach that draws on the materials science expertise within the consortium and could establish new protocols for transient gene silencing in woody perennial crops.

The funding mechanism behind the project is as distinctive as its science. The EIC Pathfinder Challenges programme, part of the European Innovation Council, supports highly innovative, high-risk scientific research with the potential to generate entirely new technologies in the future. It deliberately funds the early stages of research, when ideas are still being explored in the laboratory and there is not yet a clear commercial application. The programme’s objective is to establish the scientific and technological foundations for breakthroughs that, in the long term, can transform entire sectors or help address major societal challenges. For a crop that underpins the economies of Mediterranean regions and provides vitamin-rich food to billions of people, the societal stakes of climate-resilient citrus are considerable.

The four-year project will begin in October 2026 under proposal number 101306995, giving the consortium a defined window in which to deliver its gene discovery pipelines, transformation protocols and biofortified citrus lines. The breadth of the partnership – spanning academic plant science institutes, agricultural research organisations, materials specialists and companies – suggests a deliberate effort to cover the full pipeline from fundamental gene discovery to applied field-relevant varieties. The involvement of computational firms such as Computomics and CYBRES alongside plant science heavyweights like INRAE and CIRAD signals that the AI and data integration components are treated as core infrastructure rather than an afterthought.

For consumers and growers alike, the project’s promise is twofold: citrus trees better equipped to endure a warming, pest-pressured world, and fruit with an enhanced portfolio of health-promoting compounds. Whether engineered resilience and resveratrol-enriched oranges will reach commercial orchards remains a question for the years beyond the project’s horizon, but CitrusAld represents one of the most comprehensive European attempts to marry genomics, artificial intelligence, materials science and plant breeding in service of a single iconic crop. As climate change accelerates and the tools of biotechnology mature, the humble orange may become a showcase for how 21st-century science re-engineers the foods we have cultivated for millennia.

Subject of Research: Genetic modification of citrus crops for climate resilience and nutritional biofortification

Article Title: Universitat Jaume I leads European consortium to develop genetically modified citrus lines with greater resilience to climate change, pests and diseases

Article References: Universitat Jaume I leads European consortium to develop genetically modified citrus lines with greater resilience to climate change, pests and diseases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: citrus, genetic modification, climate change, EIC Pathfinder, Universitat Jaume I, New Genomic Techniques, RNA interference, biofortification, resveratrol, artificial intelligence, sweet orange, mandarin

To understand why this regulation matters, it helps to recall how far the underlying science has travelled since the current legal framework was drafted. Directive 2001/18/EC, the main legislation governing the environmental release of genetically modified organisms in the EU, dates back to 2001. At that time, the dominant method for creating a transgenic plant involved inserting foreign DNA more or less at random into the genome, typically through Agrobacterium-mediated transformation or particle bombardment. Regulators built a system around that reality: every organism carrying recombinant DNA was treated as a genetically modified organism, subject to case-by-case risk assessment, traceability requirements and labelling obligations, regardless of the size of the genetic change involved.

The tools available to plant scientists then changed beyond recognition. Site-directed nucleases, and above all the CRISPR-Cas systems that emerged from foundational work in the early 2010s, made it possible to edit genomes with base-pair precision. Researchers could now introduce small deletions, single-nucleotide substitutions or precisely defined insertions at chosen target sites, producing plants whose final genetic makeup may be indistinguishable from what conventional mutagenesis or natural variation could deliver. Oligonucleotide-directed mutagenesis and epigenetic modifications added further routes to targeted change. The conceptual foundation of the 2001 directive, which anchors regulation to the process used rather than the characteristics of the final product, suddenly sat uneasily alongside techniques that blur the line between engineered and naturally occurring variation.

European institutions saw the problem early. The first Working Group on New Plant Breeding Techniques was established by the European Commission in 2007, with the explicit aim of identifying legislation more appropriate to technologies developed after 2001. That group and its successors wrestled with a deceptively simple question: when a genome edit could equally have been produced by conventional breeding, should the plant be regulated as a genetically modified organism? For years the question produced legal opinions, reports and consultations but no binding answer, while breeders in North America, Japan, Argentina and elsewhere moved ahead under product-based or tiered regulatory approaches.

The turning point came from an unexpected direction. In 2018, the Court of Justice of the European Union ruled that organisms obtained by directed mutagenesis techniques fall within the scope of the GMO directive, exempting only those produced by conventional mutagenesis methods that had long been in use. The judgment meant that even a precise, transgene-free edit made with CRISPR was legally equivalent to a transgenic insertion from the 1990s. Scientists and plant breeders warned that the ruling effectively locked European researchers out of the most dynamic area of modern crop improvement, and petitions from the scientific community urged the Commission to revisit the framework. The episode became a defining case study in how process-based regulation can struggle to accommodate technological change.

The Commission responded in 2023 with a legislative proposal that distinguished between categories of plants obtained by new genomic techniques, drawing a line between edits that could have been achieved through conventional breeding and more complex alterations involving foreign genetic material. The proposal triggered intense negotiation over the criteria for the lighter-touch category, the treatment of patents on gene-edited traits, the verification of edits without transgenic intermediates, and the coexistence of new-technique plants with organic and conventional supply chains. Those debates shaped the text that the Council and Parliament ultimately approved, and they explain why adoption took as long as it did.

Regulation (EU) 2026/1388 now provides the operative answer. Plants obtained by certain new genomic techniques, and products derived from them, gain a dedicated legal pathway that reflects the nature and scale of the genetic modification involved. For the plant science community, the significance is as much symbolic as practical: the EU has acknowledged, in binding law, that the regulatory treatment of a plant should depend on what has actually been changed in its genome, not merely on the laboratory method used to change it. That shift in regulatory philosophy, from process to product characteristics, is the intellectual heart of the reform.

The practical consequences will unfold over the coming years. Breeders developing traits such as disease resistance, altered oil profiles, drought tolerance or improved nutritional composition through targeted editing will be able to plan commercialisation strategies under a framework designed for their tools rather than inherited from an earlier technological era. Public research institutes, which were among the loudest voices calling for reform, stand to benefit particularly, since the cost and uncertainty of the old GMO regime weighed most heavily on actors without the resources of multinational seed companies. At the same time, implementation will demand new technical capacities: detection and identification of edited plants in traded goods, verification dossiers, and post-market oversight all require methods and expertise that national authorities are only now beginning to build.

Open scientific questions remain. Distinguishing a targeted edit from spontaneous or induced mutation of the same kind is analytically demanding, and the technical literature continues to explore how sequencing-based and other approaches can support enforcement without imposing prohibitive burdens. The interaction between the new regulation and intellectual property law, especially the patentability of gene-edited traits versus the breeders’ exemption in plant variety rights, remains one of the most contested issues in the field. And the global regulatory landscape is far from harmonised, meaning that exporters and importers will need to navigate divergent definitions and thresholds across jurisdictions for years to come.

What the adoption of Regulation (EU) 2026/1388 demonstrates most clearly is that regulatory systems can, eventually, catch up with science, even if the journey is measured in decades rather than years. From the first Commission working group in 2007 to the final votes in 2026, the EU spent nearly twenty years reconciling a law written for transgenic technology with a world of precise genome editing. For plant scientists who watched the gap widen year after year, the new regulation is not merely a legal text but a signal that evidence-based argument can reshape policy. The challenge now shifts from drafting the rules to implementing them well, so that the promise of new genomic techniques, for agriculture, for research and for food security, can be realised within a framework the public can trust.

Subject of Research: EU regulation of plants developed with new genomic techniques

Article Title: Evolution and implementation of EU regulation on new genomic techniques

Article References: Cardi, T., & Vitale, A. (2026). Evolution and implementation of EU regulation on new genomic techniques. Nature Plants, 12(9), 1650-1655. https://doi.org/10.1038/s41477-026-02402-9

Image Credits: AI Generated

DOI: 10.1038/s41477-026-02402-9

Keywords: new genomic techniques, EU regulation, CRISPR, plant breeding, genetically modified organisms, Directive 2001/18/EC, genome editing, agricultural biotechnology, European Commission, plant science, food security, regulatory policy

The authors argue that the explanation for this paradox cannot be found in the biology of the edited plants themselves. Instead, they contend, it lies in the way the technology is embedded within broader social structures. To make that argument, they reach back several decades, before CRISPR was invented, to the work of the German-born Canadian physicist and philosopher of technology Ursula M. Franklin, who lived from 1921 to 2016. In her book The Real World of Technology, first delivered as lectures in 1989 and published in 1990, Franklin developed a framework that the Freiburg researchers believe helps explain why genome-edited crops have met such different receptions on either side of the Atlantic and across sectors of application.

Franklin’s central insight was that technologies are never merely tools. In her view, every technology is in fact an entire system, shaped jointly by regulation, markets, institutions and culture. A genome-editing enzyme such as Cas9 is, on this reading, only the visible tip of a much larger formation that includes patent regimes, seed markets, food-safety authorities, agricultural traditions, media narratives and consumer expectations. Franklin’s work explored how such technological systems influence power, authority and everyday life, and in this respect her thinking echoes ideas developed earlier by social historians and philosophers such as Michel Foucault, Lewis Mumford and Jacques Ellul, all of whom analyzed technology as a force that organizes society rather than a neutral instrument within it.

Applying this framework to CRISPR reveals why the risk-based argument familiar from plant science has failed to settle the debate. European regulation of genome-edited plants has its origins in a 2018 ruling of the Court of Justice of the European Union, which held that organisms produced by new mutagenesis techniques fall within the scope of existing genetically modified organism legislation. That judgment entrenched a regulatory pathway built on traceability and labelling requirements established for transgenic organisms, including the traceability and labelling framework laid down by European rules from 2003. Under such a system, a plant whose genome differs from a conventionally bred counterpart by only a small deletion or point mutation can nonetheless be classified, tracked and labelled as a genetically modified organism, even though the molecular outcome is one that traditional breeding could also have produced.

From a technical standpoint, the distinction is indeed difficult to defend on scientific grounds. Genome editing with CRISPR–Cas typically introduces small insertions, deletions or base substitutions at targeted loci. Conventional mutagenesis breeding, which has been practiced for decades using chemical or radiation treatments, produces random mutations across the genome and is exempt from the strict genetically modified organism rules in many jurisdictions. Site-directed nuclease editing is, in effect, a more precise version of mutagenesis, with far fewer unintended changes to monitor. The 2014 analysis by Frank Hartung and Jürgen Schiemann, cited in the commentary, examined precisely these questions of equivalence and risk. Yet, as the Freiburg team emphasizes, the regulatory treatment of a product does not track its biological properties but its production process—a decision that is legal and political rather than scientific.

The policy landscape, however, has begun to shift. In 2023 the European Commission put forward a proposal for a regulation on plants obtained by certain new genomic techniques and their food and feed, seeking to differentiate between categories of genome-edited plants according to the type of genetic change involved. That process culminated in June 2026 with Regulation (EU) 2026/1388 on plants obtained by certain new genomic techniques and their products, which amends the earlier 2017/625 regulation on official controls. This legislative move represents an attempt to build a more differentiated system, one that can distinguish targeted edits indistinguishable from conventional breeding outcomes from more extensive modifications. For the commentary’s authors, the episode illustrates Franklin’s point in real time: the technology’s fate is being decided not in the laboratory but in the architecture of rules, institutions and market arrangements that surround it.

What, then, would a sustainable innovation system for CRISPR in plant science look like? The commentary’s argument suggests several components. First, regulation must be technically coherent, meaning that the category into which a plant falls should reflect the nature and scale of the genetic change rather than the method used to create it. Second, transparency and traceability need to serve public trust rather than functioning as ends in themselves; if consumers cannot see how decisions are made, labelling schemes risk becoming symbolic battlegrounds rather than informative tools. Third, the benefits of the technology must be distributed in ways that farmers, breeders and consumers can recognize, since an innovation system that concentrates value in a few patent holders is unlikely to sustain broad social license. Fourth, public engagement has to treat citizens as participants in shaping the system, not merely as audiences to be persuaded of its safety.

The contrast between medicine and agriculture sharpens this point. In therapeutic applications, genome editing is evaluated within a well-established institutional framework of clinical trials, ethics committees and health technology assessment, and it addresses conditions that individual patients and their families experience as urgent and personal. In plant breeding, by contrast, the same molecular intervention is situated within agricultural systems marked by long-running debates over industrial farming, seed ownership, pesticide use and the concentration of the food supply. The technology is not judged in isolation; it inherits the anxieties and political commitments attached to the system it enters. Franklin’s framework makes this inheritance explicit, and it explains why campaigns that focus exclusively on communicating the molecular facts have repeatedly failed to move public opinion in the European agricultural context.

The economists’ perspective adds a further layer. The commentary invokes Kenneth Boulding, whose work on economic imagery and evolution emphasized that societies live by narratives and images as much as by material flows. Genome-edited plants, in this light, compete not only on agronomic performance but on the story they are embedded in—are they a continuation of human stewardship of crops, or an escalation of corporate control over the food chain? Building a durable innovation system means attending to that narrative infrastructure deliberately: who is seen to benefit, who is seen to decide, and what risks are seen to matter. The authors’ use of Franklin and Boulding signals that the scientific community must engage these questions on their own terms rather than dismissing them as misunderstandings of the science.

Ultimately, the Freiburg commentary makes a claim that reaches beyond plant biology to the governance of emerging technologies in general. CRISPR–Cas is a genuinely transformative tool, capable of precise, targeted and increasingly diverse genetic interventions, and its technical trajectory continues to accelerate. Whether that capability translates into societal benefit in agriculture depends on assembling the surrounding system—regulation, markets, institutions and culture—into a configuration that is scientifically sound, economically viable, socially trusted and ethically defensible. The new European regulatory framework of 2026 offers an opening, but the deeper lesson from Franklin is that no single ruling settles the matter. A sustainable innovation system is not a finished artifact but an ongoing practice of aligning technological capability with public values, and the genome-editing debate in plant science is now one of its most instructive real-world tests.

Subject of Research: Societal and regulatory dimensions of CRISPR genome editing in plant breeding

Article Title: CRISPR beyond biology: building a sustainable innovation system

Article References: Barbez, E., Boldt, J., & Kleine-Vehn, J. (2026). CRISPR beyond biology: building a sustainable innovation system. Nature Plants, 12(9), 1648-1649. https://doi.org/10.1038/s41477-026-02410-9

Image Credits: AI Generated

DOI: 10.1038/s41477-026-02410-9

Keywords: CRISPR, genome editing, plant breeding, Ursula Franklin, EU regulation, new genomic techniques, agricultural biotechnology, science policy, public acceptance, GMO legislation, innovation systems, Nature Plants

The concern driving the research is well documented. Bifidobacteria are among the earliest colonizers of the human gastrointestinal tract and dominate the gut microbiota of infants and healthy adults, and B. animalis subsp. lactis is the most commonly used probiotic in foods and supplements, with documented benefits ranging from improved colonic barrier function and mitigation of antimicrobial treatment side effects to enhanced oral health, relief of infant colic and cholesterol-lowering activity. Yet phylogenomic surveys show that tetW, which encodes a ribosomal protection protein that blocks tetracycline from binding the bacterial ribosome, is widely distributed across strains of this subspecies. The gene is frequently flanked by mobile genetic elements, raising the possibility of horizontal gene transfer to other members of the gut microbiota. Comparative analyses of tetW loci from human intestinal Bifidobacterium strains have found 98 to 100 percent identity within a 2.1 kilobase core region, and conserved sequences matching tetW, tetO and tetS have been detected in commensal and pathogenic bacteria spanning the Arcanobacterium, Streptococcus, Corynebacterium, Campylobacter and Listeria genera. The tetW locus also has a GC content of 51.9 percent, considerably lower than the 60.5 percent GC content of the BLC01 genome, a signature consistent with horizontal acquisition.

Under European Food Safety Authority guidelines, any antimicrobial resistance gene is considered a hazard and may preclude Qualified Presumption of Safety status unless its intrinsic nature is demonstrated. Recent metagenomic analyses of commercial probiotic products have detected more than 70 distinct resistance genes, including hybrid tet(W/N/W) variants often linked to integrative conjugative elements. Against this backdrop, the research team set out to eliminate the resistance trait at its source. Their approach falls under the umbrella of New Genomic Techniques, which recent EU regulation defines as a diverse group of methods capable of producing organisms with modifications equivalent to those obtainable by conventional breeding or with more complex changes. EFSA has stated that applying these techniques to microorganisms does not pose novel hazards compared with established genomic techniques or conventional mutagenesis, with respect to the technique itself, and the agency has outlined comparative risk assessment strategies based on substantial equivalence between the parental strain and the edited derivative.

The technical centerpiece of the study is the exploitation of BLC01’s own immune system. Bioinformatic analysis identified an endogenous Type I-U CRISPR-Cas system consisting of a CRISPR array with 19 spacers interspersed with a conserved 36-nucleotide direct repeat, located immediately downstream of the cas operon. Spacer analysis against viral sequence databases revealed a conserved 5′-CAC-3′ protospacer-adjacent motif. The team designed a 33-nucleotide spacer targeting the 5′ region of tetW and cloned it into a synthetic mini-CRISPR array on the pAM1 shuttle vector, complete with the native leader sequence, two direct repeats and a rho-independent transcription terminator. When expressed, this construct mimics native CRISPR activity, producing a guide RNA that directs the endogenous Cascade-Cas3 complex to the tetW locus. A two-kilobase repair template carried on the same plasmid then steered homology-directed repair, introducing seven nucleotide substitutions that create three consecutive premature stop codons at positions 62 to 64 of the TetW protein.

The editing worked with striking efficiency. Of 96 individual clones screened, two displayed a tetracycline-sensitive phenotype. The researchers cured one mutant of the editing plasmid and subjected the resulting clone, BLC01-2F3G10, to whole-genome sequencing using both Illumina and Oxford Nanopore platforms. Comparison with the wild-type genome confirmed the intended mutations in tetW and revealed only two additional changes: a single cytosine deletion in a non-coding region and an adenine-to-cytosine substitution in the lgt gene, which encodes a phosphatidylglycerol-prolipoprotein diacylglyceryl transferase. That substitution changes a threonine to a proline at the boundary of an alpha helix, but three-dimensional structural modeling showed the overall conformation of the protein remained unaltered, suggesting the mutation is functionally neutral. Crucially, because the editing plasmid was removed, the final strain carries no exogenous DNA, a feature that substantially strengthens its biosafety and regulatory profile.

The functional consequences were unambiguous. The minimum inhibitory concentration of tetracycline for the parental strain was 32 micrograms per milliliter, well above the EFSA microbiological cut-off of 8 micrograms per milliliter. After tetW inactivation, the MIC dropped to 1 microgram per milliliter, comfortably below the threshold. Growth kinetics confirmed the loss of resistance: at a sublethal tetracycline concentration of 0.5 micrograms per milliliter, the edited strain showed a marked delay in exponential growth, and at a lethal concentration of 1 microgram per milliliter it failed to grow beyond an optical density of roughly 0.1 over 24 hours, while the wild type retained partial growth. For the seven other antimicrobials tested, including ampicillin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin and chloramphenicol, only minor variations in MIC values were observed, and all remained at or below EFSA cut-offs, indicating the edit specifically abolished tetracycline resistance without altering susceptibility to unrelated drug classes.

Equally important, the edit left the probiotic machinery intact. Both strains survived three hours of exposure to pH 2, 3 and 4 with no significant differences between them, tolerated bile salt concentrations up to 2 percent, and showed similar growth kinetics under osmotic stress at sodium chloride concentrations of 2.5 to 3.5 percent. Both produced exopolysaccharides when grown on glucose, fructose, sucrose or lactose as sole carbon sources, with no differences in colony morphology. Auto-aggregation was strong in both strains, reaching 79.75 percent for the wild type and 83.30 percent for the edited derivative after four hours, and co-aggregation with Escherichia coli ATCC 25922 and Salmonella enterica UC3605 was similarly low and variable in both. Under the INFOGEST static in vitro digestion protocol, which simulates oral, gastric and intestinal phases, both strains maintained bacterial loads of approximately 8 log CFU per milliliter throughout the experiment.

Adhesion assays reinforced the picture of functional equivalence. Using Caco-2 and HT-29 human intestinal epithelial cell lines, the team found that both bifidobacterial strains adhered at levels comparable to Lacticaseibacillus rhamnosus ATCC 53103, the gold-standard positive control. On Caco-2 cells, the edited strain actually showed the highest adhesion of any strain tested, reaching 90.56 percent, while the negative control, Lactobacillus delbrueckii subsp. lactis DSM 2072, managed only 6.63 percent. On HT-29 monolayers quantified by real-time PCR, BLC01 and BLC01-2F3G10 exhibited adhesion levels 10.45 and 8.74 times higher than the positive control, respectively, with no statistically significant difference between them. These results indicate that tetW inactivation did not disturb the surface-associated proteins and envelope components that mediate host interaction, colonization and immunomodulatory effects.

A final and critical question was stability. Resistance genes can sometimes revert or be regained under selective pressure, so the team passaged the edited strain for five consecutive days in medium containing tetracycline at 0.1 and 0.5 micrograms per milliliter, concentrations above the reported minimal selective concentration of 0.01 micrograms per milliliter but below the mutant’s MIC. After 122 generations, no revertant colonies capable of growing at the 8 micrograms per milliliter cut-off were detected. By eliminating a mobile, widely conserved resistance gene without introducing new determinants, the edited strain reduces the theoretical risk of horizontal gene transfer within the gut resistome, a concern underscored by metagenomic evidence linking probiotic-associated tetracycline resistance to mobile elements. The authors argue that minimal, well-characterized edits of this kind, which abolish resistance without deleting large genomic regions, are particularly attractive from a regulatory standpoint because they reduce the likelihood of unintended effects and simplify molecular characterization. While in vivo studies will be needed to confirm the strain’s behavior in the complex intestinal ecosystem, the study demonstrates that endogenous CRISPR editing can serve as a precision safety tool, providing a generalizable framework for developing next-generation probiotics that are both effective and aligned with evolving regulatory and societal expectations.

Subject of Research: Removal of the tetracycline resistance gene tetW from Bifidobacterium animalis subsp. lactis using its endogenous CRISPR-Cas system under a safe-by-design framework

Article Title: Endogenous CRISPR‐Based Removal of Tetracycline Resistance in Bifidobacterium animalis subsp. lactis Through a Safe‐by‐Design Approach

Article References: Endogenous CRISPR‐Based Removal of Tetracycline Resistance in Bifidobacterium animalis subsp. lactis Through a Safe‐by‐Design Approach. (n.d.). https://doi.org/10.1111/1751-7915.70443

Image Credits: AI Generated

DOI: 10.1111/1751-7915.70443

Keywords: CRISPR, probiotics, Bifidobacterium animalis subsp. lactis, antimicrobial resistance, tetW, tetracycline, genome editing, safe-by-design, New Genomic Techniques, horizontal gene transfer, EFSA, gut microbiota